DK2464371T3 - Methods for preventing or treating metabolic syndrome - Google Patents

Methods for preventing or treating metabolic syndrome Download PDF

Info

Publication number
DK2464371T3
DK2464371T3 DK10808688.5T DK10808688T DK2464371T3 DK 2464371 T3 DK2464371 T3 DK 2464371T3 DK 10808688 T DK10808688 T DK 10808688T DK 2464371 T3 DK2464371 T3 DK 2464371T3
Authority
DK
Denmark
Prior art keywords
peptide
metabolic syndrome
use according
aromatic
blood
Prior art date
Application number
DK10808688.5T
Other languages
Danish (da)
English (en)
Inventor
Hazel H Szeto
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Application granted granted Critical
Publication of DK2464371T3 publication Critical patent/DK2464371T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK10808688.5T 2009-08-12 2010-08-11 Methods for preventing or treating metabolic syndrome DK2464371T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23327509P 2009-08-12 2009-08-12
PCT/US2010/045160 WO2011019809A1 (en) 2009-08-12 2010-08-11 Methods for preventing or treating metabolic syndrome

Publications (1)

Publication Number Publication Date
DK2464371T3 true DK2464371T3 (en) 2016-06-27

Family

ID=43586452

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10808688.5T DK2464371T3 (en) 2009-08-12 2010-08-11 Methods for preventing or treating metabolic syndrome

Country Status (10)

Country Link
US (4) US20110039766A1 (enExample)
EP (4) EP3067061A1 (enExample)
JP (5) JP5909182B2 (enExample)
CN (3) CN107412724A (enExample)
CA (1) CA2770688C (enExample)
DK (1) DK2464371T3 (enExample)
ES (1) ES2576746T3 (enExample)
HK (1) HK1247820A1 (enExample)
HU (1) HUE029550T2 (enExample)
WO (1) WO2011019809A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3292868A1 (en) 2009-08-24 2018-03-14 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CA2776581C (en) * 2009-10-05 2020-12-15 Cornell University Methods for the prevention or treatment of heart failure
JP2013516426A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 冠状動脈バイパス移植術を行うための方法
WO2013149172A1 (en) * 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
CA2880648A1 (en) 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
WO2014066419A2 (en) * 2012-10-22 2014-05-01 Stealth Peptides International, Inc. Methods for reducing risks associated with heart failure and factors associated therewith
JP2016506391A (ja) * 2012-12-06 2016-03-03 ステルス ペプチドズ インターナショナル インコーポレイテッド ペプチド治療薬およびその使用方法
EP2961378B1 (en) 2013-03-01 2019-10-23 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US20170057995A1 (en) * 2013-09-27 2017-03-02 Cornell University Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction
US9943563B2 (en) 2013-12-02 2018-04-17 Stealth Biotherapeutics Corp Compositions and methods for treating vitiligo
WO2017066659A1 (en) * 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Jag1 expression predicts therapeutic response in nash
EP3442990A4 (en) 2016-04-11 2019-12-18 Carnot, LLC CHIRALE PEPTIDE
WO2018107690A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法
CN108210902A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂肪肝的药物及其用途
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
JP7171671B2 (ja) * 2020-10-22 2022-11-15 野村マイクロ・サイエンス株式会社 超純水製造システム及び超純水製造方法
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ES2085865T3 (es) * 1988-06-30 1996-06-16 Astra Ab Analogos de dermorfina, sus metodos de preparacion, composiciones farmaceuticas, y metodos de tratamiento terapeutico que los emplean.
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5468798A (en) * 1994-02-18 1995-11-21 Whitford Corporation Basecoat for a coating system
DE69630918T2 (de) * 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CA2329709A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
ATE432993T1 (de) * 1999-10-04 2009-06-15 Univ New Jersey Med Tar rna bindende peptide
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP3479838A1 (en) * 2003-02-04 2019-05-08 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
EP1625149B1 (en) * 2003-05-01 2016-02-17 Cornell Research Foundation, Inc. Method and carrier complexes for delivering molecules to cells
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1699476A1 (en) * 2003-11-28 2006-09-13 DeveloGen Aktiengesellschaft Method for preventing and treating diabetes using dg119
EP1734963A4 (en) * 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
CN103784937B (zh) * 2005-09-16 2017-04-26 科内尔研究基金会 用于减少cd36表达的方法
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
US20080161400A1 (en) * 2006-10-26 2008-07-03 Xenoport, Inc. Use of forms of propofol for treating diseases associated with oxidative stress
JP5453320B2 (ja) * 2008-02-07 2014-03-26 コーネル ユニヴァーシティー インスリン抵抗性を防止または処置するための方法
US8143219B2 (en) * 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
CA2776581C (en) * 2009-10-05 2020-12-15 Cornell University Methods for the prevention or treatment of heart failure

Also Published As

Publication number Publication date
CN105031605A (zh) 2015-11-11
EP3067061A1 (en) 2016-09-14
HUE029550T2 (en) 2017-03-28
EP2464371B1 (en) 2016-03-16
JP6271785B2 (ja) 2018-01-31
EP3251686A1 (en) 2017-12-06
HK1247820A1 (zh) 2018-10-05
JP2017132782A (ja) 2017-08-03
JP5909182B2 (ja) 2016-04-26
EP2464371A1 (en) 2012-06-20
EP3427746A1 (en) 2019-01-16
US20190209641A1 (en) 2019-07-11
EP2464371A4 (en) 2013-02-20
US20160199435A1 (en) 2016-07-14
WO2011019809A1 (en) 2011-02-17
JP2019104768A (ja) 2019-06-27
CA2770688A1 (en) 2011-02-17
US20110039766A1 (en) 2011-02-17
CA2770688C (en) 2018-06-05
ES2576746T3 (es) 2016-07-11
JP2018052983A (ja) 2018-04-05
CN107412724A (zh) 2017-12-01
US20180104304A1 (en) 2018-04-19
JP2016041762A (ja) 2016-03-31
CN102647994A (zh) 2012-08-22
JP2013501802A (ja) 2013-01-17

Similar Documents

Publication Publication Date Title
DK2464371T3 (en) Methods for preventing or treating metabolic syndrome
US12102659B2 (en) Methods for the prevention or treatment of heart failure
JP2019069985A (ja) ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
HK1224948A1 (en) Methods for preventing or treating metabolic syndrome
HK1242194A1 (en) Methods for preventing or treating metabolic syndrome
HK1174844A (en) Methods for preventing or treating metabolic syndrome
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis